BXMT Q2 2025 Earnings Call Transcript [Globe and Mail, The (Toronto, Canada)]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Globe and Mail, The
Chief Financial Officer — Cecilia Jones Chief Commercial Officer — Tsveta Milanova Chief Medical Officer — Sarah Gheuens Operator — [Operator's full name not disclosed] TAKEAWAYS Net revenue -- $12.5 million, up 45% year over year and 44% sequentially from Q1, attributed to continued commercial execution in PKD, an extra week of ordering, and increased units processed directly by the specialty pharmacy. PYRUKYND patient enrollment -- 248 patients completed prescription enrollment forms, rising 6% sequentially; 142 patients currently treated, increasing 4% from Q1 2025. Cash, cash equivalents, and marketable securities -- $1.3 billion at quarter-end, supporting disciplined investment in the pipeline and commercial build-out. Cost of sales -- $1.7 million for the quarter. R&D expenses -- $91.9 million, increasing $14.5 million from the prior year due primarily to a $10 million milestone payment to Alnylam for AG-236 development. SG&A expenses -- $45.9 million, up $1
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Choppy Trading And Rich P/E Multiple [Yahoo! Finance]Yahoo! Finance
- Brown Advisory Large-Cap Growth Strategy Q1 2026 Portfolio Review [Seeking Alpha]Seeking Alpha
- Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial ResultsBusiness Wire
- Aerska Strengthens Leadership and Board with Key Appointments to Advance Systemically Delivered RNA Medicines for the Brain [Yahoo! Finance]Yahoo! Finance
- RNAi?????2035??25?6,720?????????CAGR9.30%???????????????????????? : ???????????????????? [CNET News]CNET News
ALNY
Earnings
- 2/12/26 - Beat
ALNY
Sec Filings
- 4/7/26 - Form 4
- 4/7/26 - Form 3
- 4/6/26 - Form ARS
- ALNY's page on the SEC website